Cross-agency comparison: 🇪🇺 EMA leads with 70 documents in 90 days

FDA vs EMA vs MHRA vs Health Canada — who's most active?

The EMA appears to be the most active environment by volume, with FDA and MHRA running at a similar but notably lower pace and Health Canada trailing behind; this may indicate that Europe is currently generating the densest stream of regulatory signals for sponsors to track. Companies planning multi-market submissions should consider that the higher-output agencies will likely demand more monitoring, faster internal review cycles, and more frequent dossier updates, while the lower-output markets may still require tailored attention rather than being treated as secondary. Strategically, this could suggest prioritizing regulatory intelligence and authoring resources toward the EMA-led workstream, with a coordinated global core that can be adapted efficiently for FDA, MHRA, and Health Canada rather than rebuilt market by market.